Oncology Drugs

A novel AI-designed drug that can cross the formidable blood-brain barrier has entered U.S. trials, targeting some of the deadliest brain tumors.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

Landmark Phase 3 data for HBI-8000 not only offers new hope for melanoma patients but validates a powerful "China-to-global" drug development strategy.

Erasca secures $550M to advance its attack on the notorious RAS/MAPK pathway. A look at the science, the strategy, and what it means for oncology.

Amplia Therapeutics' new patent application for novel FAK inhibitors extends protection to 2046, signaling a major play in oncology and fibrosis markets.

Preclinical data shows GLIX1 can make PARP inhibitors effective in previously unresponsive tumors, a potential game-changer for 50% of ovarian cancer patients.

Avacta taps veteran dealmaker Dr. Patrick Vink as it nears a pivotal data reveal for its pre|CISION® platform, signaling a shift from R&D to high-stakes commercial strategy.

A new deal to develop cancer drugs reveals a seismic shift: China is no longer just a market, but a core engine in a new global innovation network.

Revolution Medicines' zoldonrasib delivers high response rates in trials for RAS G12D pancreatic cancer, offering a beacon of hope against a lethal disease.

Molecular Partners and Orano Med begin human trials for a novel radiopharmaceutical, hoping to unlock a new front against small cell lung cancer.

For women with resistant ovarian cancer, options are few. A new drug, NTB-928, uses a dual-key design to unlock the immune system against tumors.

A surge in biotech innovation is set to transform the high-grade glioma market. With a pipeline of targeted drugs and vaccines, a once-stagnant field is now a beacon of hope.

Oryzon Genomics secures a dual funding package, navigating market jitters to accelerate its pioneering cancer and psychiatric drug pipelines with EU backing.

Intensity Therapeutics shows promising results for its cancer-killing drug, but can it navigate the biotech funding crunch and land a vital pharma partner?

As Merck preps for its August 4th earnings call, investors look past Q2 numbers to see if a flurry of deals and pipeline wins can build a new empire.

Allarity Therapeutics just secured a patent until 2042 for its cancer diagnostic. Is this the key to unlocking personalized treatment or a risky biotech bet?

New data reveals how Genelux’s oncolytic virus reawakens chemotherapy's power, offering a potential lifeline in a notoriously difficult-to-treat cancer.

With an $85M insider-led round and a seasoned M&A expert as CEO, Flare Therapeutics sharpens its focus on a novel prostate cancer drug, FX-111.

Plus Therapeutics rebrands to Cerenome, signaling a major pivot to an integrated platform combining diagnostics, radiotherapeutics, and AI for CNS cancers.